Chronic Heart Failure Clinical Trial
Official title:
Effects of a Mindfulness-Based Intervention on Symptoms and Signs, Well-Being and Health in Patients With Chronic Heart Failure
Verified date | May 2021 |
Source | Göteborg University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with Chronic Heart Failure diagnosed and conventional treated, but still symptomatic (i.e. breathlessness, fatigue) is invited. Eligible patients are randomised to (1) care as usual (i.e. optimized medical treatment) or (2) care as usual (i.e. optimized medical treatment) in combination with an 8-week mindfulness-based educational and training program. Specific research questions: - How are self-reported symptoms of breathlessness, fatigue, difficult sleeping, anxiety and depression affected by a mindfulness-based educational and training program (MBI)? - Does the implementation of an 8-week Mindfulness-based program have any impact on personal experiences of well-being and health? - What effects does an 8-week MBI have on objective signs of importance for the progression of heart failure?
Status | Completed |
Enrollment | 50 |
Est. completion date | December 31, 2013 |
Est. primary completion date | December 31, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosed chronic heart (CHF) failure by echocardiography - Functional class II-IV according to the New York Heart Association (NYHA) - Symptoms of breathlessness and/or tiredness rated 2-5 by patients using five-point scales, ranging from asymptomatic (1) to symptoms at rest (5) - Stable condition, that is no deterioration of heart failure symptoms or new CHF drug or hospitalizations because of decompensated heart failure within the last four weeks Exclusion Criteria: - Severe psychiatric diagnosis (requiring treatment) - Severe substance abuse (documented in journal) - Severe somatic disease with short expected survival (i.e., malignancy) - Communication difficulties (i.e., impaired vision or hearing, need of an interpreter to understand Swedish) - Cognitive or adherence difficulties (documented in journal) - Unstable angina pectoris - Post-partum cardiomyopathy - Ongoing participation in any other interventional study - Unwillingness to participate |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Göteborg University | Sahlgrenska University Hospital, Sweden |
Antonovsky A. The structure and properties of the sense of coherence scale. Soc Sci Med. 1993 Mar;36(6):725-33. — View Citation
Arias AJ, Steinberg K, Banga A, Trestman RL. Systematic review of the efficacy of meditation techniques as treatments for medical illness. J Altern Complement Med. 2006 Oct;12(8):817-32. Review. — View Citation
Baer RA, Mindfulness Training as a clinical intervention: A Conceptual and Emperical Review. Clin Psychol Sci Prac 2003;10(2):125-143.
Barnes S, Gott M, Payne S, Parker C, Seamark D, Gariballa S, Small N. Prevalence of symptoms in a community-based sample of heart failure patients. J Pain Symptom Manage. 2006 Sep;32(3):208-16. — View Citation
Bennett JA, Riegel B, Bittner V, Nichols J. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002 Jul-Aug;31(4):262-70. — View Citation
Bernardi L, Spadacini G, Bellwon J, Hajric R, Roskamm H, Frey AW. Effect of breathing rate on oxygen saturation and exercise performance in chronic heart failure. Lancet. 1998 May 2;351(9112):1308-11. — View Citation
Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002 Feb;52(2):69-77. Review. — View Citation
Chang BH, Hendricks A, Zhao Y, Rothendler JA, LoCastro JS, Slawsky MT. A relaxation response randomized trial on patients with chronic heart failure. J Cardiopulm Rehabil. 2005 May-Jun;25(3):149-57. — View Citation
Curiati JA, Bocchi E, Freire JO, Arantes AC, Braga M, Garcia Y, Guimarães G, Fo WJ. Meditation reduces sympathetic activation and improves the quality of life in elderly patients with optimally treated heart failure: a prospective randomized study. J Altern Complement Med. 2005 Jun;11(3):465-72. — View Citation
Davidson RJ, Kabat-Zinn J, Schumacher J, Rosenkranz M, Muller D, Santorelli SF, Urbanowski F, Harrington A, Bonus K, Sheridan JF. Alterations in brain and immune function produced by mindfulness meditation. Psychosom Med. 2003 Jul-Aug;65(4):564-70. — View Citation
Dupuy HJ. The Psychological General Well-Being (PGWB) Index. New York: Le Jacq; 1984
Ekman I, Cleland JG, Swedberg K, Charlesworth A, Metra M, Poole-Wilson PA. Symptoms in patients with heart failure are prognostic predictors: insights from COMET. J Card Fail. 2005 May;11(4):288-92. Erratum in: J Card Fail. 2005 Jun;11(5):404. — View Citation
Ekman I, Granger B, Swedberg K, Stenlund H, Boman K. Measuring shortness of breath in heart failure (SOB-HF): development and validation of a new dyspnoea assessment tool. Eur J Heart Fail. 2011 Aug;13(8):838-45. doi: 10.1093/eurjhf/hfr062. — View Citation
Ekman I, Kjellström B, Falk K, Norman J, Swedberg K. Impact of device-guided slow breathing on symptoms of chronic heart failure: a randomized, controlled feasibility study. Eur J Heart Fail. 2011 Sep;13(9):1000-5. doi: 10.1093/eurjhf/hfr090. Epub 2011 Jul 28. — View Citation
Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nurs. 2008 Apr;62(1):107-15. doi: 10.1111/j.1365-2648.2007.04569.x. — View Citation
Falk K, Granger BB, Swedberg K, Ekman I. Breaking the vicious circle of fatigue in patients with chronic heart failure. Qual Health Res. 2007 Oct;17(8):1020-7. — View Citation
Falk K, Swedberg K, Gaston-Johansson F, Ekman I. Fatigue is a prevalent and severe symptom associated with uncertainty and sense of coherence in patients with chronic heart failure. Eur J Cardiovasc Nurs. 2007 Jun;6(2):99-104. Epub 2006 Jul 10. — View Citation
Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today. 2004 Feb;24(2):105-12. Review. — View Citation
Heidenreich PA, Fonarow GC, Breathett K, Jurgens CY, Pisani BA, Pozehl BJ, Spertus JA, Taylor KG, Thibodeau JT, Yancy CW, Ziaeian B. 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2020 Nov 24;76(21):2527-2564. doi: 10.1016/j.jacc.2020.07.023. Epub 2020 Nov 2. — View Citation
Hirshberg MJ, Goldberg SB, Rosenkranz M, Davidson RJ. Prevalence of harm in mindfulness-based stress reduction. Psychol Med. 2020 Aug 18:1-9. doi: 10.1017/S0033291720002834. [Epub ahead of print] — View Citation
Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005 Nov;15(9):1277-88. — View Citation
Jaarsma T, Hill L, Bayes-Genis A, La Rocca HB, Castiello T, Celutkiene J, Marques-Sule E, Plymen CM, Piper SE, Riegel B, Rutten FH, Ben Gal T, Bauersachs J, Coats AJS, Chioncel O, Lopatin Y, Lund LH, Lainscak M, Moura B, Mullens W, Piepoli MF, Rosano G, Seferovic P, Strömberg A. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021 Jan;23(1):157-174. doi: 10.1002/ejhf.2008. Epub 2020 Oct 20. — View Citation
Janson Fagring A, Gaston-Johansson F, Danielson E. Description of unexplained chest pain and its influence on daily life in men and women. Eur J Cardiovasc Nurs. 2005 Dec;4(4):337-44. Epub 2005 Nov 10. — View Citation
Janssen DJ, Spruit MA, Uszko-Lencer NH, Schols JM, Wouters EF. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med. 2011 Jun;14(6):735-43. doi: 10.1089/jpm.2010.0479. Epub 2011 Apr 21. — View Citation
Kabat-Zinn J, Lipworth L, Burney R. The clinical use of mindfulness meditation for the self-regulation of chronic pain. J Behav Med. 1985 Jun;8(2):163-90. — View Citation
Kecklund G, Akerstedt T. The psychometric properties of the Karolinska Sleep Questionnaire. J Sleep Res 1992;6:221-29.
Kenne Sarenmalm E, Mårtensson LB, Andersson BA, Karlsson P, Bergh I. Mindfulness and its efficacy for psychological and biological responses in women with breast cancer. Cancer Med. 2017 May;6(5):1108-1122. doi: 10.1002/cam4.1052. Epub 2017 Apr 18. — View Citation
Krippendorf K. Content analysis. An introduction to its methodology. 6th ed. London: Sage; 2004.
Krittanawong C, Kumar A, Wang Z, Narasimhan B, Jneid H, Virani SS, Levine GN. Meditation and Cardiovascular Health in the US. Am J Cardiol. 2020 Sep 15;131:23-26. doi: 10.1016/j.amjcard.2020.06.043. Epub 2020 Jun 30. — View Citation
Langius A, Björvell H, Antonovsky A. The sense of coherence concept and its relation to personality traits in Swedish samples. Scand J Caring Sci. 1992;6(3):165-71. — View Citation
Levine GN, Lange RA, Bairey-Merz CN, Davidson RJ, Jamerson K, Mehta PK, Michos ED, Norris K, Ray IB, Saban KL, Shah T, Stein R, Smith SC Jr; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Hypertension. Meditation and Cardiovascular Risk Reduction: A Scientific Statement From the American Heart Association. J Am Heart Assoc. 2017 Sep 28;6(10). pii: e002218. doi: 10.1161/JAHA.117.002218. Review. — View Citation
Meditation practice for health. State of research. Evidens report/technology assessment. Agency for healthcare research and quality. University of Alberta Evidence-based Practice Centre. Number 155, 2007,
Meleis AI, Sawyer LM, Im EO, Hilfinger Messias DK, Schumacher K. Experiencing transitions: an emerging middle-range theory. ANS Adv Nurs Sci. 2000 Sep;23(1):12-28. Review. — View Citation
Norman J, Fu M, Ekman I, Björck L, Falk K. Effects of a mindfulness-based intervention on symptoms and signs in chronic heart failure: A feasibility study. Eur J Cardiovasc Nurs. 2018 Jan;17(1):54-65. doi: 10.1177/1474515117715843. Epub 2017 Jun 22. — View Citation
Parén P, Schaufelberger M, Björck L, Lappas G, Fu M, Rosengren A. Trends in prevalence from 1990 to 2007 of patients hospitalized with heart failure in Sweden. Eur J Heart Fail. 2014 Jul;16(7):737-42. doi: 10.1002/ejhf.109. Epub 2014 May 26. — View Citation
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592. Epub 2016 May 20. — View Citation
RICKHAM PP. HUMAN EXPERIMENTATION. CODE OF ETHICS OF THE WORLD MEDICAL ASSOCIATION. DECLARATION OF HELSINKI. Br Med J. 1964 Jul 18;2(5402):177. — View Citation
Saha S, Jarl J, Gerdtham UG, Sundquist K, Sundquist J. Economic evaluation of mindfulness group therapy for patients with depression, anxiety, stress and adjustment disorders compared with treatment as usual. Br J Psychiatry. 2020 Apr;216(4):197-203. doi: 10.1192/bjp.2018.247. — View Citation
Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000 Aug;23(4):334-40. Review. — View Citation
Schenström O. (in Swedish) (2007) Mindfulness i vardagen - vägar till medveten närvaro. 10th edition Viva Publishing House by Ljungbergs sätteri i Köping, printed 2009 by ScandBook AB in Falun, Sweden.
Schenström O. (in Swedish) Här & Nu - Ett program för medveten närvaro; 2013. The MBI program is available from web site: http://www.mindfulnesscenter.se Accessed April 15, 2021, but is not linked due to the site also includes other mindfulness-based educational program, products and services.
Scott-Sheldon LAJ, Gathright EC, Donahue ML, Balletto B, Feulner MM, DeCosta J, Cruess DG, Wing RR, Carey MP, Salmoirago-Blotcher E. Mindfulness-Based Interventions for Adults with Cardiovascular Disease: A Systematic Review and Meta-Analysis. Ann Behav Med. 2020 Jan 1;54(1):67-73. doi: 10.1093/abm/kaz020. — View Citation
Steptoe A, Mohabir A, Mahon NG, McKenna WJ. Health related quality of life and psychological wellbeing in patients with dilated cardiomyopathy. Heart. 2000 Jun;83(6):645-50. — View Citation
Sullivan M, Karlsson J, Ware JE Jr. The Swedish SF-36 Health Survey--I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med. 1995 Nov;41(10):1349-58. — View Citation
Sullivan M, Karlsson J. The Swedish SF-36 Health Survey III. Evaluation of criterion-based validity: results from normative population. J Clin Epidemiol. 1998 Nov;51(11):1105-13. — View Citation
Sullivan MJ, Wood L, Terry J, Brantley J, Charles A, McGee V, Johnson D, Krucoff MW, Rosenberg B, Bosworth HB, Adams K, Cuffe MS. The Support, Education, and Research in Chronic Heart Failure Study (SEARCH): a mindfulness-based psychoeducational intervention improves depression and clinical symptoms in patients with chronic heart failure. Am Heart J. 2009 Jan;157(1):84-90. doi: 10.1016/j.ahj.2008.08.033. — View Citation
Sundquist J, Lilja Å, Palmér K, Memon AA, Wang X, Johansson LM, Sundquist K. Mindfulness group therapy in primary care patients with depression, anxiety and stress and adjustment disorders: randomised controlled trial. Br J Psychiatry. 2015 Feb;206(2):128-35. doi: 10.1192/bjp.bp.114.150243. Epub 2014 Nov 27. — View Citation
Sundquist J, Palmér K, Johansson LM, Sundquist K. The effect of mindfulness group therapy on a broad range of psychiatric symptoms: A randomised controlled trial in primary health care. Eur Psychiatry. 2017 Jun;43:19-27. doi: 10.1016/j.eurpsy.2017.01.328. Epub 2017 Feb 8. — View Citation
Sundquist J, Palmér K, Memon AA, Wang X, Johansson LM, Sundquist K. Long-term improvements after mindfulness-based group therapy of depression, anxiety and stress and adjustment disorders: A randomized controlled trial. Early Interv Psychiatry. 2019 Aug;13(4):943-952. doi: 10.1111/eip.12715. Epub 2018 Jul 3. — View Citation
Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol. 2000 Aug;68(4):615-23. — View Citation
Viveiros J, Chamberlain B, O'Hare A, Sethares KA. Meditation interventions among heart failure patients: An integrative review. Eur J Cardiovasc Nurs. 2019 Dec;18(8):720-728. doi: 10.1177/1474515119863181. Epub 2019 Jul 23. Review. — View Citation
Vuckovic KM, Fink AM. The 6-min walk test: is it an effective method for evaluating heart failure therapies? Biol Res Nurs. 2012 Apr;14(2):147-59. doi: 10.1177/1099800411403918. Epub 2011 May 17. — View Citation
Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res. 2001;10(5):405-13; discussion 415-20. — View Citation
Wu JR, Lennie TA, Frazier SK, Moser DK. Health-Related Quality of Life, Functional Status, and Cardiac Event-Free Survival in Patients With Heart Failure. J Cardiovasc Nurs. 2016 May-Jun;31(3):236-44. doi: 10.1097/JCN.0000000000000248. — View Citation
Yohannes AM, Willgoss TG, Baldwin RC, Connolly MJ. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry. 2010 Dec;25(12):1209-21. doi: 10.1002/gps.2463. Review. — View Citation
Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. Eur J Cardiovasc Nurs. 2005 Sep;4(3):198-206. — View Citation
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. — View Citation
* Note: There are 57 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Heart rate | Change from baseline to follow-up at week 10, in heart rate (beats/min), will be measured in sitting position after rest (>5 min) using an automated non-invasive monitor (Omron Memory Intelli Sense, model 705 IT; Omron Healthcare, Hoofddorp, The Netherlands). With a lower heart rate frequency representing a better prognostic sign. | 10 weeks | |
Other | Respiratory rate | Change from baseline to follow-up at week 10, in respiratory rate, will be assessed manually using the pulse clock, at rest within a set of 60 s. With a calmer breathing rate representing a better sign, and higher rates to be a worsening heart failure sign, as linked to fluid retention in the body and decompensation. | 10 weeks | |
Other | Functional classification | Change from baseline to follow-up at week 10, in New York Heart Association (NYHA class). With the NYHA class based on patient-reported symptoms on five-point Likert scale (breathlessness and tiredness) as related to physical exertion. Patient response alternatives ranged from (1) 'I am never breathless/tired' to (5) 'when I am at rest', with each symptom reported separately. With a lower NYHA class indicating lower severity degree of symptoms and improved physical function. | 10 weeks | |
Other | Breathlessness related to physical exertion | Change from baseline to follow-up at week 10, in the patient-reported severity of breathlessness related to physical activity, using five-point Likert scale. Patients' response alternatives ranged from: (1) asymptomatic 'I am never breathless'; (2) 'When I am walking up the stairs (one floor) or in a slope at normal pace'; (3) 'Walking at normal pace on a flat surface (< 200 m)'; (4) 'Walking slowly on flat surface (< 100 m) or during washing or dressing'; up to (5) 'When I am at rest'. | 10 weeks | |
Other | Tiredness related to physical exertion | Change from baseline to follow-up at week 10, in the patient-reported severity of tiredness, related to physical activity, using five-point Likert scale. Patients' response alternatives ranged from (1) asymptomatic 'I am never tired'; (2) 'When I am walking up the stairs (one floor) or in a slope at normal pace'; (3) 'Walking at normal pace on a flat surface (< 200 m)'; (4) 'Walking slowly on flat surface (< 100 m) or during washing or dressing'; up to (5) ('When I am at rest'). | 10 weeks | |
Other | Functional capacity | Change from baseline to follow-up at week 10, measured in distance (in meter) walked at the 6-min walk test. With a longer distance walked in 6 minutes, indicating improved functional capacity. Additional outcome assessed as 'objective sign', in participants in the second phase of the study. | 10 weeks | |
Other | Shortness of breath | Change from baseline to follow-up at week 10, will be measured and described in self-reported experiences of breathing and shortness of breath explored in semi structured interviews, guided by an extended assessment tool "Experiences of Breathing and Shortness of breath" (Exp-BeSoB), in development within the project. The Exp-BeSoB includes both open-ended questions, where participants are allowed to explore their own experiences in several dimensions, and pre-formulated descriptors, and self-rating scales related to shortness of breath experiences. With lower scores indicating alleviated breathing symptoms. | 10 weeks | |
Other | Other symptoms | Change from baseline to follow-up at week 10, will be measured in six other self-reported symptoms (ankle swelling, impaired appetite; nausea, pain at rest/moving, thirst/dryness in the throat, and unsteadiness/dizziness) commonly reported by patients with chronic heart failure. Occurrence of symptom within a timeframe of "last week" ("no/yes"), and the degree of symptom severity self-reported by participants using 11-point numerical rating scale (NRS) ranging from 0 ("not at all bothersome") to 10 ("worst possible"), with higher rating degree indicating more severe symptom experiences. | 10 weeks | |
Other | Health self-rated on Visual Analogue Scale | Change from baseline to follow-up at week 10, in health will be measured using self-rating scales. In the first pilot (2010 - 2011) health was also assessed on an ungraded vertical visual analog scale (VAS), with the anchor points "worse health" and "best health" (at the top of the scale). The scale was in 2013, changed into a horizontal 11-point numerical rating scale (NRS) ranging from 0 ("worst possible health") to 10 ("best possible health"). Due to different scale measures, outcome was not possible to include in statistical analysis. Health measures on VAS were used in the 2nd sub-project to identify outliers among participants who didn't answer the SF-36, in the first pilot. | 10 weeks | |
Other | Well-being self-rated on Likert-scale | Change from baseline to follow-up at week 10, in well-being as measured on self-rating scales. In the first pilot (2010 - 2011) well-being was also assessed on a 5-point Likert scale (1-5), with the anchor points (1) "no well-being" and (5) "best possible well-being". The scale was in 2013, also changed into a horizontal 11-point numerical rating scale (NRS) ranging from 0 to 10 with the anchor points (1) "worst possible well-being" and (10) "best possible well-being". Due to different scale measures, outcome was not possible to include in statistical analysis. | 10 weeks | |
Primary | Self-reported impact of fatigue | Change from baseline to follow-up at week 10, will be measured at the Fatigue Severity Scale (FSS), a self-administered questionnaire including nine items investigating the impact of disabling fatigue on daily functioning during the past week. Grading of each item ranges from 1 to 7, with the total possible fatigue sum score ranging from 9 to 63, and higher scores indicating higher levels of indexed impact of fatigue. The FSS had not previously been tested in a heart failure population, and no cut-off score was found. The FSS was provided at visits and answered at home, and sent in to University address. | 10 weeks | |
Secondary | Anxiety | Change from baseline to follow-up at week 10, will be measured at the Hospital Anxiety and Depression Scale (HADS). The HADS is a self-administered questionnaire with two sub-scales to detect possible presence of anxiety (HADS-A) and/or depression (HADS-D). Both sub-scales include 7 items, with four-point scales ranging from 0 to 3, with total sum-score ranging from 0-21, and defined as 0-7 (normal), 8-10 (possible case), and 11-21 (probable case) of anxiety disorders or depression, and the patient in need of additional psychiatric treatment. Optimal cut-off for both subscales is set to =8. The HADS was provided at visits, answered at home, and sent to University address. | 10 weeks | |
Secondary | Depression | Change from baseline to follow-up at week 10, will be measured at the Hospital Anxiety and Depression Scale (HADS). The HADS is a self-administered questionnaire with two sub-scales to detect possible presence of anxiety (HADS-A) and/or depression (HADS-D). Both sub-scales include 7 items, with four-point scales ranging from 0 to 3, with total sum-score ranging from 0-21, and defined as 0-7 (normal), 8-10 (possible case), and 11-21 (probable case) of anxiety disorders or depression, and the patient in need of additional psychiatric treatment. Optimal cut-off for both subscales is set to =8. The HADS was provided at visits, answered at home, and sent to University address. | 10 weeks | |
Secondary | Psychological and General Well-Being | Change from baseline to follow-up at week 10, will be measured at the Psychological and General Well-Being (PGWB) index. The PGWB is a 22-item self-administered questionnaire designed to measure "self-representations of intrapersonal affective or emotional states reflecting a sense of subjective well-being or distress. The six response options were coded 1-6 in accordance with Swedish studies, and the total PGWB sum score was ranging from 22 to 132, with defined categories (1) score 22-82 (Severe distress); (2) score 83-94 (Moderate distress); score 95-132 (Positive well-being). The PGWB was provided at visits, answered at home, and sent in to University address. | 10 weeks | |
Secondary | Sense of coherence | Change from baseline to follow-up at week 10, will be measured at the self-administered questionnaire Sense of coherence (SOC-13) total index. The SOC-13 consisting of 13 items, all with seven-point scale and two anchoring responses. With higher scores indicating higher personal capabilities to perceive the world and stressful events in life as comprehensible, manageable, and meaningful defined as high SOC. The psychometric tested Swedish version of SOC-13, and the total score categories defined as: 30-60 (Low SOC); 61-75 (Moderate SOC); 76-91 (High SOC) is used. The SOC-13 was provided at visits, answered at home, and sent in to University address. | 10 weeks | |
Secondary | Health | Change from baseline to follow-up at week 10, on self-reported health, will be measured at the Swedish version of the 36-item Short Form Health Survey (SF-36) General Health (GH) Index. The SF-36 GH index consists of five items, with questions focusing participants' perception of their health, with five response choices each, and higher points indicating better health. The SF-36 questionnaire were included in the first phase (pilot 1), then temporary removed. The value of health status as measured in the SF-36, was reconsidered 2012 and the instrument was reinstated in 2013 (pilot 2). The SF-36 was provided at visits, answered at home, and sent in to University address. | 10 weeks | |
Secondary | Self-reported symptoms of impaired sleep | Change from baseline to follow-up at week 10, will be measured at the Karolinska Sleep Questionnaire - sleep quality index (KSQ-sqi). Which is a sub-scale including four questions, with high scores indicating good sleep quality. The KSQ was provided at visits, answered at home, and sent to University address. | 10 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03597646 -
The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure
|
N/A | |
Terminated |
NCT04065997 -
Apogee International
|
||
Withdrawn |
NCT03675113 -
Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT02916160 -
Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study
|
Phase 4 | |
Completed |
NCT03126656 -
Effects of Testosterone on Myocardial Repolarization
|
Phase 4 | |
Completed |
NCT02268500 -
VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
|
Phase 4 | |
Completed |
NCT02247245 -
The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.
|
N/A | |
Completed |
NCT01919918 -
Muscle Afferent Feedback Effects in Patients With Heart Failure
|
Phase 1 | |
Terminated |
NCT01906957 -
Cognition and Exercise Training
|
N/A | |
Not yet recruiting |
NCT01669395 -
Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial
|
N/A | |
Completed |
NCT00984529 -
Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia
|
N/A | |
Recruiting |
NCT00863421 -
Sleep Disordered Breathing in Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT02840565 -
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
|
Phase 1 | |
Completed |
NCT02441218 -
Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study
|
Phase 3 | |
Completed |
NCT00149409 -
Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure
|
Phase 2/Phase 3 | |
Terminated |
NCT05532046 -
A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)
|
Phase 1 | |
Recruiting |
NCT04984928 -
Readmission Risk of Patients With Heart Failure.
|
||
Completed |
NCT02814097 -
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
Active, not recruiting |
NCT05560737 -
ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
|
||
Recruiting |
NCT03286127 -
Palliative Outcome Evaluation Muenster I
|